Stay updated on Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Sign up to get notified when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.

Latest updates to the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRemoved the Interstitial lung disease 2 item and the Genetic and Rare Diseases Information Center resources from the page.SummaryDifference0.1%

- Check18 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive content or layout changes are visible in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedFooter revision tag updated from v3.4.0 to v3.4.1. No changes to study information or navigation.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded Show glossary toggle; updated metadata labels to include 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with Revision set to v3.4.0, and removed the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and Revision: v3.3.4.SummaryDifference0.1%

Stay in the know with updates to Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.